Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,978 public trials 744 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Torrance, California, United States
  • GSK Investigational Site Fort Collins, Colorado, United States
  • GSK Investigational Site Hartford, Connecticut, United States
View all 53 locations
View Trial Details
Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site Coeur d'Alene, Idaho, United States
View all 51 locations
View Trial Details
Completed

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02014480

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Humenné, Slovakia
  • GSK Investigational Site Kráľovský Chlmec, Slovakia
  • GSK Investigational Site Poprad, Slovakia
  • GSK Investigational Site Šaľa, Slovakia
View all 21 locations
View Trial Details
Completed

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

NCT01018186

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Oxford, Alabama, United States
  • GSK Investigational Site Huntington Beach, California, United States
  • GSK Investigational Site Mission Viejo, California, United States
  • GSK Investigational Site Rolling Hills Estates, California, United States
View all 47 locations
View Trial Details
Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

NCT01395888

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • GSK Investigational Site Rosario, Santa Fe Province, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
View all 55 locations
View Trial Details
Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01165138

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Bell Gardens, California, United States
  • GSK Investigational Site Huntington Beach, California, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 70 locations
View Trial Details

Related conditions